The Full Frame

Our new protocol was just listed on ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT01012830

Outlook is good, we anticipate recruitment, analysis, and publication to occur swiftly and efficiently.

HupA, an alkaloid initially identified from the Chinese herbal medicine Huperia serrata, is a potent reversible acetyl cholinesterase (AChE) inhibitor with additional unique properties including NMDA-receptor antagonist properties, neuroprotective and antioxidant effects. In animal studies, HupA was shown to possess greater inhibitory, longer-lasting, and more selective effects on AChE activity than donepezil. In clinical studies HupA improved memory, mood, and activities of daily living in patients with Alzheimer’s dementia. Adverse effects have been reported at a very low rate in all the clinical trials, and are mainly cholinergic, such as dizziness, nausea, gastrointestinal symptoms, headaches and depressed heart rate. Thus, HupA is an attractive option which may have beneficial effects not only on cognitive but also functional domains of schizophrenia.

Today marks the launch of my public sister site to this page, ResearchOrders.com. My goal with creating this page was to give people in the research field a place to network and ask questions without fear of their information being used for information mining from a site like facebook.com.

I have noticed the lack of sites for research networking on the internet. This really puzzles me as Research is a strongly collaborative endeavor and, many times, hinges on your social alliances.

Most of my personal content will continue to be posted here and it will be either linked to or copy-pasted into my forum.

Please pass this information on to anyone interested you may know.

http://www.researchorders.com